10-Q quarterly report · filed Oct 29, 2026

Baxter International (BAX) Q3 2026 10-Q Quarterly Report

Short answer

Baxter International (BAX) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $3.0B (up 5.0% year over year) with net income of $294M.

Q3 2026 key financials · XBRL

Revenue
$3.0B
+5.0% YoY · +0.5% QoQ
Net income
$294M
+739.1% YoY · +133.3% QoQ
Operating margin
7.6%
Gross margin
33.4%
EPS (diluted)
$0.57
+733.3% YoY · +137.5% QoQ

Source: XBRL data from the Baxter International (BAX) Q3 2026 10-Q on SEC EDGAR. USD.

Baxter International Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $2.976B, up $141M from $2.835B YoY, with Medical Products & Therapies strongest at 6% growth
  • Gross margin 33.4% vs 33.5% YoY, excluding special items down 1.1 percentage points
  • Advanced Surgery best-performing line, sales up 12%; Other sales weakest, $68M vs $85M YoY
  • Operating cash flow $1.07B vs $355M YoY; debt repayments $600M and capital expenditures $363M
  • Outlook: tariffs, supply constraints, inflation and geopolitical uncertainty remain headwinds; no meaningful Novum LVP sales during shipment holds

Risk Factors

  • No material changes to risk factors disclosed in Baxter’s 2025 Annual Report

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Baxter International quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.